Medpace Holdings Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 536.35.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Medpace Holdings Inc's Score
Industry at a Glance
Industry Ranking
55 / 404
Overall Ranking
150 / 4592
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Hold
Current Rating
536.351
Target Price
-2.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Medpace Holdings Inc Highlights
StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.11B.
Overvalued
The company’s latest PE is 38.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.75M shares, decreasing 5.75% quarter-over-quarter.
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEOTroendle (August J)
Websitehttps://investor.medpace.com/
FAQs
What is the current price of Medpace Holdings Inc (MEDP)?
The current price of Medpace Holdings Inc (MEDP) is 557.900.
What is the symbol of Medpace Holdings Inc?
The ticker symbol of Medpace Holdings Inc is MEDP.
What is the 52-week high of Medpace Holdings Inc?
The 52-week high of Medpace Holdings Inc is 626.255.
What is the 52-week low of Medpace Holdings Inc?
The 52-week low of Medpace Holdings Inc is 250.050.
What is the market capitalization of Medpace Holdings Inc?
The market capitalization of Medpace Holdings Inc is 15.68B.
What is the net income of Medpace Holdings Inc?
The net income of Medpace Holdings Inc is 404.34M.
Is Medpace Holdings Inc (MEDP) currently rated as Buy, Hold, or Sell?
According to analysts, Medpace Holdings Inc (MEDP) has an overall rating of Hold, with a price target of 536.351.
What is the Earnings Per Share (EPS TTM) of Medpace Holdings Inc (MEDP)?
The Earnings Per Share (EPS TTM) of Medpace Holdings Inc (MEDP) is 14.665.